What’s New in Continuous Glucose Monitoring Technology?
How the latest innovations in continuous glucose monitoring are transforming diabetes management
Continuous Glucose Monitoring (CGM) technology is changing the way people monitor and manage diabetes. Traditionally, individuals with diabetes have relied on finger-prick blood tests to measure glucose levels at different times throughout the day. Although this method remains useful, it provides only a snapshot of blood glucose at a particular moment. CGM technology offers a more complete picture by tracking glucose levels continuously and helping users understand how their bodies respond to food, exercise, medication, stress, and daily activities.
In recent years, significant advances in sensor technology, artificial intelligence, wearable devices, mobile applications, and automated insulin delivery have made CGM systems more convenient, accurate, and accessible. These developments are moving diabetes management towards a more personalised and proactive approach.
As healthcare becomes increasingly digital, an important question emerges: What is new in continuous glucose monitoring, and how could these innovations improve the lives of people living with diabetes?
1. Smaller, Smarter, and Longer-Lasting Sensors
Earlier generations of glucose monitors were relatively bulky and sometimes required frequent calibration using traditional finger-prick tests. Modern systems are generally more compact, discreet, and easier to operate.
Leading manufacturers, including Dexcom, Abbott, and Medtronic, have introduced devices with improved wearability and connectivity.
For example, the Dexcom G7 15 Day extends sensor wear time to 15 days, reducing the frequency of sensor replacement. The FreeStyle Libre 3 Plus also offers up to 15 days of use. These improvements can reduce inconvenience, simplify daily routines, and potentially lower the ongoing burden of diabetes management.
Modern sensors can also transmit glucose readings automatically to compatible smartphones, receivers, or insulin delivery systems. This means users can monitor glucose trends without repeatedly scanning the sensor in systems designed for automatic transmission.
Another important development is improved accuracy. Modern factory-calibrated sensors have reduced the need for routine finger-prick calibration. However, accuracy can still vary between devices and under different physiological conditions.
2. Artificial Intelligence Is Making Glucose Monitoring More Intelligent
Artificial intelligence (AI) is becoming an important part of modern diabetes technology.
Traditional glucose monitoring mainly provides information about current glucose levels and recent changes. Newer digital platforms increasingly analyse patterns in glucose data to help users understand what may be influencing their readings.
AI-supported applications can help identify:
Glucose increases after particular meals.
Repeated episodes of low glucose during the night.
Changes associated with physical activity.
Patterns related to sleep and daily routines.
Periods when glucose levels remain outside recommended ranges.
Some systems also offer personalised insights and food-logging features that connect meals with glucose responses.
For example, Dexcom has reported developments in AI-powered food logging for its Stelo platform. Such tools aim to make meal recording easier and provide more useful context for understanding glucose patterns.
However, AI should be considered a decision-support tool rather than a replacement for medical professionals. Users should not independently change insulin doses or other prescribed treatments based solely on automated recommendations.
3. Real-Time Alerts and Predictive Monitoring
One of the most valuable features of modern CGM systems is their ability to provide real-time glucose alerts.
Users can receive notifications when glucose levels rise above or fall below personalised thresholds. These alerts are particularly important for people who experience hypoglycaemia, especially during sleep or physical activity.
Some systems provide predictive alerts that warn users when glucose levels appear likely to become dangerously low. This gives individuals more time to respond.
For example, someone exercising may notice that glucose is falling faster than expected. With an early warning, they can follow their healthcare professional's advice to prevent a potentially serious episode of hypoglycaemia.
Remote monitoring is another significant development. Certain CGM platforms allow family members, parents, and healthcare professionals to view glucose information through secure data-sharing applications.
This can be particularly useful for children with diabetes, older adults, and people who require additional support.
The technology is also helping doctors make more informed decisions during consultations. Instead of relying entirely on occasional glucose measurements, healthcare professionals can examine detailed patterns over days or weeks.
4. The Emergence of Dual Glucose and Ketone Monitoring
Major 2026 developmentOne of the most significant recent developments in glucose-monitoring technology is the introduction of devices that can monitor both glucose and ketones.
On August 25, 2026, the US Food and Drug Administration (FDA) authorised Abbott's Libre Duo 10 Day system, described as the first wearable device to continuously monitor both glucose and ketone levels.
This is an important development because ketones can rise when the body does not have sufficient insulin and begins breaking down fat for energy. Excessive ketone accumulation can lead to diabetic ketoacidosis (DKA), a potentially life-threatening complication, particularly among people with type 1 diabetes.
Previously, people generally needed separate testing methods to monitor ketones. A continuous dual-monitoring system offers a different approach by tracking both measurements through one wearable device.
The Libre Duo measures glucose and ketones in fluid beneath the skin and sends information to a compatible smartphone. It can also provide alerts when ketone levels reach concerning thresholds.
The technology could help patients and caregivers recognise warning signs earlier and seek medical assistance when necessary. It does not replace medical assessment or emergency treatment for suspected DKA.
5. Over-the-Counter CGM Devices Are Expanding Access
Another important development is the growing availability of CGM devices without a traditional prescription requirement in certain markets.
Previously, CGM technology was primarily designed for people diagnosed with diabetes, particularly those using insulin. However, manufacturers and regulators are increasingly exploring access for additional groups.
In the United States, Dexcom's Stelo glucose biosensor received over-the-counter clearance in 2024 for adults who do not use insulin.
An additional milestone occurred on June 12, 2026, when the FDA cleared the system for children aged two years and older who do not use insulin, under specified indications and adult supervision.
This development illustrates how glucose-monitoring technology is expanding beyond conventional diabetes management.
Such devices may help eligible users understand glucose patterns associated with meals, exercise, and lifestyle changes. However, an OTC glucose monitor is not a general-purpose diagnostic device, and its suitability depends on the person's health circumstances and the product's approved indications.
Importantly, not every CGM is appropriate for people using insulin or those at risk of severe hypoglycaemia. Users must select devices according to their medical needs.
6. Integration with Automated Insulin Delivery Systems
Perhaps the most transformative development in diabetes care is the integration of CGM technology with automated insulin delivery (AID) systems.
These systems connect glucose sensors with insulin pumps through computer algorithms.
The CGM continuously provides glucose information, while the algorithm uses these readings to adjust insulin delivery within the system's approved operating limits.
Some systems can automatically increase, decrease, or temporarily suspend insulin delivery depending on glucose trends and predicted requirements.
This technology is commonly known as a hybrid closed-loop system or an artificial pancreas.
Although these systems do not completely eliminate the need for user involvement, they can reduce the burden of diabetes management.
Users may still need to announce meals, administer meal-related insulin, respond to alerts, and monitor the device.
Recent research has shown improvements in time in range and reductions in hypoglycaemia with automated insulin delivery compared with some conventional treatment approaches.
The integration of CGM sensors with insulin pumps represents an important step towards more personalised and automated diabetes care.
7. Better Data Sharing Between Patients and Healthcare Professionals
Modern CGM systems are also improving communication between patients and medical professionals.
Cloud-based platforms allow glucose information to be securely shared with authorised healthcare providers. Doctors can review glucose patterns before or during appointments and identify areas requiring attention.
One important measurement is Time in Range (TIR), which refers to the percentage of time a person's glucose remains within an agreed target range.
For many non-pregnant adults with diabetes, a commonly used target is 70–180 mg/dL, with a general goal of spending more than 70% of the day within this range. However, individual targets may differ.
Other important measurements include:
Time Below Range (TBR): The percentage of time glucose levels remain below the target range.
Time Above Range (TAR): The percentage of time glucose levels remain above the target range.
Glucose Management Indicator (GMI): An estimate of average glucose based on CGM data.
Glucose variability: The degree to which glucose levels fluctuate.
These measurements provide a more detailed picture of glucose management than a single reading or HbA1c result alone.
The growing use of digital health platforms may also support remote consultations, allowing healthcare professionals to provide guidance without requiring every patient to visit a clinic physically.
8. Non-Invasive Glucose Monitoring: Is Finger-Prick Testing Finally Disappearing?
Traditional CGM devices use a small sensor inserted just beneath the skin to measure glucose in interstitial fluid. Although this method is less painful than repeated finger-prick testing, it still requires a sensor attached to the body.
Researchers are exploring alternative technologies that could measure glucose without breaking the skin.
These include:
Optical sensors that use light to detect changes associated with glucose.
Spectroscopy-based technologies that analyse how light interacts with biological tissues.
Sweat-based sensors that investigate glucose-related chemical signals.
Radiofrequency and other electromagnetic sensing techniques.
The possibility of monitoring glucose through a smartwatch or wearable patch is attracting considerable scientific and commercial interest.
However, there is an important distinction between research prototypes and clinically validated medical devices. As of November 2026, non-invasive glucose monitoring remains an evolving research area. Consumer smartwatches should not be assumed to provide medically reliable glucose measurements unless they have appropriate regulatory authorisation.
Future developments could make glucose monitoring more comfortable and accessible, but further research is necessary to establish accuracy, reliability, and clinical safety.
9. Challenges: What Still Needs Improvement?
Despite remarkable progress, CGM technology still faces several challenges.
Cost and affordability: CGM sensors and compatible devices can be expensive, particularly for individuals who need continuous monitoring throughout the year. In developing countries, including Pakistan, affordability and availability remain important barriers.
Sensor accuracy: Although modern devices have improved significantly, readings can sometimes differ from blood glucose measurements. Glucose changes in interstitial fluid may also lag behind changes in blood glucose.
Skin irritation: Some users experience itching, allergic reactions, or discomfort from sensor adhesives.
Technical problems: Bluetooth interruptions, connectivity issues, application failures, and sensor errors can interfere with monitoring.
Data privacy: CGM applications collect sensitive health information. Protecting personal medical data and ensuring secure information sharing are essential.
Overdependence on technology: Continuous glucose information can sometimes create anxiety or excessive concern about normal glucose fluctuations. Users need appropriate education to interpret their readings.
Addressing these challenges will be essential to ensuring that technological progress translates into better healthcare outcomes.
10. What Does the Future Hold for CGM Technology?
The future of continuous glucose monitoring is likely to involve greater personalisation, improved sensor performance, and closer integration with other healthcare technologies.
Several developments are particularly promising.
1. Longer-lasting sensors: Researchers and manufacturers are working towards longer sensor life, improved comfort, and fewer replacements.
2. Smarter AI applications: Advanced algorithms may provide more personalised insights by combining glucose information with nutrition, exercise, sleep, and other lifestyle data.
3. Multi-analyte monitoring: Future wearable devices may measure several important biological markers alongside glucose, potentially providing a more comprehensive picture of metabolic health.
4. Improved automated insulin delivery: Better integration between sensors, algorithms, and insulin pumps could reduce the daily workload associated with diabetes management.
5. More accessible technology: Greater competition, wider availability, and improvements in manufacturing could help reduce costs and expand access.
6. Non-invasive monitoring: Continued research may eventually produce reliable glucose-monitoring methods that do not require sensors beneath the skin.
A 2026 review of diabetes technology highlights the growing importance of AI, digital health platforms, automated insulin delivery, and connected medical devices. It also stresses that affordability, safety, interoperability, and equitable access must remain priorities.
Conclusion: A New Era in Diabetes Management
Continuous Glucose Monitoring technology has progressed from a relatively specialised medical tool to an increasingly important part of modern diabetes care.
Smaller sensors, longer wear times, real-time alerts, artificial intelligence, remote monitoring, and automated insulin delivery are transforming how people understand and manage their glucose levels.
The emergence of dual glucose and ketone monitoring in 2026 represents another significant milestone, demonstrating that wearable medical technology is moving towards more comprehensive health monitoring.
However, innovation must go hand in hand with affordability, clinical reliability, patient education, and equitable access.
For millions of people living with diabetes, CGM technology offers more than glucose readings. It offers greater awareness, improved opportunities for timely intervention, and the possibility of a less burdensome daily routine.
The next generation of glucose monitoring will not simply tell people what their glucose level is. It will increasingly help them understand why it changes, recognise potential risks, and work with healthcare professionals to make better-informed decisions.
The future of diabetes management is continuous, connected, intelligent, and increasingly personalised.
References and international research sources
The article incorporates information and research from international medical publications, regulatory authorities, and medical technology organisations.
US Food and Drug Administration (2026): FDA authorises the first wearable device that continuously monitors both ketone levels and blood sugar. Read FDA announcement .
US Food and Drug Administration (2026): Clearance of the first over-the-counter CGM for children. Read FDA announcement .
Diabetes technology review (2026): Advances in continuous glucose monitoring and their impact on glycaemic control in diabetes. Read research review .
Technology in Diabetes: A Year in Review (2026): Developments in monitoring, AI, automated insulin delivery, and digital healthcare. Read research article .
Dexcom Annual Report (2025): Sensor improvements, 15-day wear technology, and AI-powered food logging. Read annual report .
National Center for Biotechnology Information: Monitoring technologies and continuous glucose monitoring systems. Read medical reference .
Diabetes Technology Society (2026): Consensus guideline on performance requirements for CGM systems. Read guidelines .